Amphastar Pharmaceuticals Debt to Equity Ratio 2012-2026 | AMPH
Current and historical debt to equity ratio values for Amphastar Pharmaceuticals (AMPH) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Amphastar Pharmaceuticals debt/equity for the three months ending March 31, 2026 was 0.77.
| Amphastar Pharmaceuticals Debt/Equity Ratio Historical Data | |||
|---|---|---|---|
| Date | Long Term Debt | Shareholder's Equity | Debt to Equity Ratio |
| 2026-03-31 | $0.88B | $0.77B | 1.13 |
| 2025-12-31 | $0.84B | $0.79B | 1.07 |
| 2025-09-30 | $0.89B | $0.78B | 1.15 |
| 2025-06-30 | $0.86B | $0.76B | 1.13 |
| 2025-03-31 | $0.88B | $0.75B | 1.17 |
| 2024-12-31 | $0.85B | $0.73B | 1.15 |
| 2024-09-30 | $0.82B | $0.73B | 1.12 |
| 2024-06-30 | $0.78B | $0.71B | 1.09 |
| 2024-03-31 | $0.90B | $0.67B | 1.34 |
| 2023-12-31 | $0.87B | $0.64B | 1.37 |
| 2023-09-30 | $0.95B | $0.60B | 1.60 |
| 2023-06-30 | $0.79B | $0.59B | 1.34 |
| 2023-03-31 | $0.23B | $0.55B | 0.41 |
| 2022-12-31 | $0.21B | $0.53B | 0.40 |
| 2022-09-30 | $0.22B | $0.51B | 0.44 |
| 2022-06-30 | $0.22B | $0.50B | 0.45 |
| 2022-03-31 | $0.24B | $0.48B | 0.49 |
| 2021-12-31 | $0.23B | $0.45B | 0.51 |
| 2021-09-30 | $0.22B | $0.43B | 0.52 |
| 2021-06-30 | $0.20B | $0.47B | 0.43 |
| 2021-03-31 | $0.20B | $0.45B | 0.43 |
| 2020-12-31 | $0.18B | $0.45B | 0.41 |
| 2020-09-30 | $0.16B | $0.45B | 0.36 |
| 2020-06-30 | $0.16B | $0.44B | 0.36 |
| 2020-03-31 | $0.15B | $0.42B | 0.35 |
| 2019-12-31 | $0.16B | $0.43B | 0.37 |
| 2019-09-30 | $0.15B | $0.43B | 0.35 |
| 2019-06-30 | $0.17B | $0.43B | 0.39 |
| 2019-03-31 | $0.16B | $0.38B | 0.43 |
| 2018-12-31 | $0.15B | $0.36B | 0.41 |
| 2018-09-30 | $0.14B | $0.34B | 0.41 |
| 2018-06-30 | $0.13B | $0.32B | 0.41 |
| 2018-03-31 | $0.12B | $0.33B | 0.38 |
| 2017-12-31 | $0.12B | $0.33B | 0.35 |
| 2017-09-30 | $0.11B | $0.33B | 0.32 |
| 2017-06-30 | $0.11B | $0.33B | 0.33 |
| 2017-03-31 | $0.11B | $0.33B | 0.34 |
| 2016-12-31 | $0.10B | $0.33B | 0.30 |
| 2016-09-30 | $0.10B | $0.33B | 0.31 |
| 2016-06-30 | $0.10B | $0.31B | 0.33 |
| 2016-03-31 | $0.10B | $0.30B | 0.33 |
| 2015-12-31 | $0.10B | $0.30B | 0.32 |
| 2015-09-30 | $0.11B | $0.28B | 0.39 |
| 2015-06-30 | $0.11B | $0.29B | 0.40 |
| 2015-03-31 | $0.12B | $0.28B | 0.42 |
| 2014-12-31 | $0.11B | $0.28B | 0.38 |
| 2014-09-30 | $0.12B | $0.28B | 0.42 |
| 2014-06-30 | $0.11B | $0.29B | 0.38 |
| 2014-03-31 | $0.09B | $0.25B | 0.37 |
| 2013-12-31 | $0.09B | $0.25B | 0.35 |
| 2013-09-30 | $0.00B | $0.00B | 0.00 |
| 2013-06-30 | $0.00B | $0.00B | 0.00 |
| 2013-03-31 | $0.00B | $0.00B | 0.00 |
| 2012-12-31 | $0.08B | $0.23B | 0.36 |
| 2012-09-30 | $0.00B | 0.00 | |
| 2012-06-30 | $0.00B | 0.00 | |
| 2012-03-31 | $0.00B | 0.00 | |
| 2011-12-31 | $0.00B | $0.00B | 0.00 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $0.924B | $0.720B |
| Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable and inhalation products. The company products include Enoxaparin Sodium Injection; Amphadase; Cortrosyn for Injection; and prefilled disposable emergency syringes for crash cart use. Amphastar Pharmaceuticals, Inc. is headquartered in Rancho Cucamonga, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| BridgeBio Pharma (BBIO) | United States | $14.460B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Personalis (PSNL) | United States | $0.630B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |